The Company is a company mainly engaged in the development of biopharmaceuticals. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
The Company was established on February 16, 2016. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 19, 2018.
Headquarters
2F, 16, Daewangpangyyo-Ro 712Beon-Gil, Bundang-Gu, Seongnam-Si, Gyeonggi-Do
Seongnam; Gyeonggi;
Contact Details: Purchase the Abl Bio Inc. report to view the information.
Website: http://www.ablbio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service